Short answer
SANUWAVE Health, Inc. (SNWV) filed an 8-K current report with the SEC on April 16, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 references financial results, but the provided excerpt contains only incorporation-by-reference legal language.
SANUWAVE Health, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 references financial results, but the provided excerpt contains only incorporation-by-reference legal language
- No earnings figures, reporting period details, or operating metrics available in the supplied text
Item EX-99.1 · Exhibit EX-99.1
- Preliminary Q1 2026 revenue $9.6–$9.7M, up 3–4% year over year
- Results within prior guidance but near its lower end after several sizable deals slipped beyond March 31
- Wound-care reimbursement changes for skin substitutes and allografts caused customer caution and activity pullback
- Management maintaining investment in Ultramist despite near-term market disruption
- Preliminary figures remain subject to quarter-end close adjustments; finalized results expected in May
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other SANUWAVE Health, Inc. 8-K filings
Get the next SNWV 8-K as it lands
Follow SNWV for push alerts, or ask the research agent what this filing means.